Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis

Journal of Medicinal Chemistry

Volumn 44, Issue 23, 2001, Pages 3786-3794

  Costantino, G ^a   Macchiarulo, A ^a   Camaioni, E ^a   Pellicciari, R ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1(2H) PHTHALAZINONE DERIVATIVE; 4 AMINO 1,8 NAPHTHALIMIDE; 6(5H) PHENANTHRIDINONE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; 8 METHYL 2 (4' NITROPHENYL)QUINAZOLIN 4 ONE; BENZAMIDE DERIVATIVE; BENZOYLENUREA DERIVATIVE; CHLORTHENOXAZIN DERIVATIVE; NEUROPROTECTIVE AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NU 1064; PD 128763; POLY(ADENOSINE DIPHOSPHATE RIBOSE)POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; BINDING AFFINITY; BRAIN ISCHEMIA; BRAIN PROTECTION; CEREBROVASCULAR DISEASE; CRYSTALLOGRAPHY; ENZYME INHIBITION; MOLECULAR INTERACTION; MOLECULAR MODEL; NERVE CELL NECROSIS; PROTEIN LIGAND DOCKING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REGRESSION ANALYSIS;

CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; LIGANDS; MODELS, MOLECULAR; NAPHTHALENES; PHENANTHRIDINES; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINAZOLINES;

EID: 0035829430     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010116l     Document Type: Article

References (30)

1. Poly(ADP-ribose) polymerase-1 in the nervous system
2. J. Structure and function of poly(ADP-ribose) polymerase
3. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy
4. Poly(ADP-ribose) polymerase-1: What have we learned from the deficient mouse model?
5. The neuroprotective effect of cerebral poly(ADP-ribose)polymerase inhibition in a rat model of global ischemia
6. The effect of reperfusion on neuroprotection using an inhibitor of poly(ADP-ribose) polymerase
7. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion
8. Ischemic brain injury is mediated by the activation of poly (ADP-ribose)polymerase
9. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia
10. Ligands for glutamate receptors: Design and therapeutic prospects
11. Excitotoxicity in neurological disorders-the glutamate paradox
12. Poly (ADP-ribose) polymerasem, nitric oxide and cell death
13. Posttreatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage infocal ischemia
14. The neuroprotective effect of cerebral poly(ADPribose)polymerase inhibition in a rat model of global ischemia
15. Inhibition of poly(ADP-ribose) polymerase: Reduction of ischemic injury and attenuation of N-methyl-D-aspartate-induced neurotransmitter dysregulation
16. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase
17. Dihydroisoquinolinones: The design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase
18. Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)
19. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase
20. Structure of the catalytic fragment of poly(ADP-ribose) polymerase from chicken
21. Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling
22. Crystallization and x-ray crystallographic analysis of recombinant chicken poly-(ADP-ribose) polymerase catalytic domain produced in Sf9 insect cells
23. Energy functions for peptides and proteins. 1. Derivation of a consistent force field including the hydrogen bond from the amide crystals
24. Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4
25. Receptor surface models. 1. Definition and construction
26. Receptor surface models. 2. Application to quantitative structure-activity relationships studies
27. Receptor-based 3D QSAR analysis of estrogen receptor ligands-merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods
28. 3D-QSAR methods on the basis ofligand-receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands
29. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP- ribose) polymerase inhibitors NU1025 and NU1064
30. Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo